Alert: Federal Executive Order Fast-Tracks Psychedelic Research & FDA Review

Former US President Donald Trump signed an executive order in April aimed at lightening regulations around psychedelic research and fast-tracking FDA review of new medicines. This action marks a significant pivot away from 56 years of federal drug policy, with potential implications for the accelerated development and approval of psychedelic-based therapies. The order signals a federal intent to streamline processes for psychedelic research and may impact the regulatory environment for businesses and researchers in this space.